Vanda Pharmaceuticals to Attend Mizuho Neuro & Ophthalmology Summit 2025

WASHINGTON, May 16, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that it will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025. The event is scheduled for Wednesday, May 21, 2025, in New York City.

The summit serves as an opportunity for Vanda to connect with investors and discuss advancements in their neurological and ophthalmological therapeutic developments. These discussions aim to highlight the company’s commitment to addressing high unmet medical needs.

“We are excited to showcase our innovations and engage with the investment community at the Mizuho Neuro & Ophthalmology Summit,” said Kevin Moran, Senior Vice President and Chief Financial Officer of Vanda Pharmaceuticals. “This event allows us to share our progress and vision for the future of biopharmaceuticals in these critical areas of health.”

Vanda has established itself as a prominent player in the global biopharmaceutical industry, focusing on creating therapies that significantly enhance patient lives. The company continues to prioritize innovative solutions that meet the evolving needs of patients globally.

For more information about Vanda Pharmaceuticals Inc., please visit their website and follow them on X @vandapharma.